Pharma Focus Asia

ClearPoint Neuro Enters into Licence Agreement with UCB

Wednesday, May 24, 2023

ClearPoint Neuro announced that it has entered into a multi-year licence agreement with UCB to partner on drug delivery platforms for UCB’s gene therapy portfolio.

Under the terms of the licence agreement, UCB will utilise ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialisation of UCB’s gene therapy products. ClearPoint Neuro will receive success-based milestone payments.

This partnership with UCB, will focus on innovation through the adoption of next generation science and new technologies. ClearPoint Neuro enables to become a strong strategic fit for UCB committed to dedicated innovation in the neurology space with a unique portfolio of navigation and drug delivery tools.
 

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference